The retiring Glaxo ceo agreed to speak with BBC Radio this morning after the European Commission licensed the drugmaker’s Prepandrix avian flu vaccine. The first few minutes were spent chatting about the vaccine, which JP says is about “preparing people for the worst.” But then the discussion turned toward the controversy over Paxil side effects and the release of clinical trial data.
You may recall that, two months ago, the UK’s Medicines and Healthcare products Agency decided not to pursue criminal charges, although the agency did chastise Glaxo for failing to release more quickly clinical trial data about suicidal risk in youngsters. This was the result of a four-year investigation that examined more than 1 million documents about Paxil, or Seroxat, as it’s called in the UK.
At the time, the MHRA requested Glaxo publicly release all the documents, and the BBC interviewer persists in asking JP whether the release would take place and whether Glaxo would ensure that such episodes never occur again. JP replies that Glaxo has been transparent and spent a great deal of time sorting through the documents. An argument ensues and JP cuts the conversation short.
But does he ever answer the question? Listen to the BBC to find out… The 10-minute interview starts at 1 hour and 32 minutes into the broadcast, but you can get there quickly by hitting the fast forward button.